Johnson & Johnson (JNJ.N)
JNJ.N on New York Stock Exchange
126.83USD
23 Apr 2018
126.83USD
23 Apr 2018
Change (% chg)
$0.17 (+0.13%)
$0.17 (+0.13%)
Prev Close
$126.66
$126.66
Open
$126.88
$126.88
Day's High
$127.30
$127.30
Day's Low
$125.78
$125.78
Volume
2,104,714
2,104,714
Avg. Vol
2,436,759
2,436,759
52-wk High
$148.32
$148.32
52-wk Low
$122.15
$122.15
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 2.06 | December | 25 Apr 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 7 | 7 | 7 | 7 |
| (2) OUTPERFORM | 4 | 4 | 4 | 4 |
| (3) HOLD | 8 | 8 | 8 | 9 |
| (4) UNDERPERFORM | 1 | 1 | 1 | 1 |
| (5) SELL | 2 | 2 | 2 | 2 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.41 | 2.41 | 2.41 | 2.43 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 15 | 20,380.70 | 20,762.00 | 20,123.10 | 20,207.50 |
| Quarter Ending Sep-18 | 15 | 20,325.20 | 20,576.00 | 20,138.00 | 19,748.80 |
| Year Ending Dec-18 | 20 | 81,509.00 | 82,392.00 | 80,959.00 | 79,416.50 |
| Year Ending Dec-19 | 21 | 84,017.30 | 86,255.00 | 80,657.00 | 82,194.50 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 18 | 2.06 | 2.25 | 2.00 | 1.97 |
| Quarter Ending Sep-18 | 18 | 2.03 | 2.14 | 1.83 | 1.92 |
| Year Ending Dec-18 | 22 | 8.13 | 8.19 | 8.08 | 7.65 |
| Year Ending Dec-19 | 23 | 8.58 | 8.98 | 7.91 | 8.09 |
| LT Growth Rate (%) | 8 | 8.01 | 9.70 | 4.30 | 6.17 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-18 | 19,460.40 | 20,009.00 | 548.56 | 2.82 |
| Quarter Ending Dec-17 | 20,072.50 | 20,195.00 | 122.52 | 0.61 |
| Quarter Ending Sep-17 | 19,282.80 | 19,650.00 | 367.23 | 1.90 |
| Quarter Ending Jun-17 | 18,934.90 | 18,839.00 | 95.86 | 0.51 |
| Quarter Ending Mar-17 | 18,037.00 | 17,766.00 | 270.96 | 1.50 |
| Earnings (per share) | ||||
| Quarter Ending Mar-18 | 2.02 | 2.06 | 0.04 | 2.07 |
| Quarter Ending Dec-17 | 1.72 | 1.74 | 0.02 | 0.96 |
| Quarter Ending Sep-17 | 1.80 | 1.90 | 0.10 | 5.46 |
| Quarter Ending Jun-17 | 1.80 | 1.83 | 0.03 | 1.92 |
| Quarter Ending Mar-17 | 1.77 | 1.83 | 0.06 | 3.21 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 20,380.70 | 20,285.70 | 20,257.40 | 20,250.70 | 20,207.50 |
| Quarter Ending Sep-18 | 20,325.20 | 20,368.30 | 20,380.20 | 20,375.90 | 19,748.80 |
| Year Ending Dec-18 | 81,509.00 | 81,338.90 | 81,114.80 | 81,102.50 | 79,416.50 |
| Year Ending Dec-19 | 84,017.30 | 84,081.20 | 84,192.80 | 84,132.90 | 82,194.50 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 2.06 | 2.06 | 2.07 | 2.07 | 1.97 |
| Quarter Ending Sep-18 | 2.03 | 2.05 | 2.05 | 2.05 | 1.92 |
| Year Ending Dec-18 | 8.13 | 8.11 | 8.10 | 8.10 | 7.65 |
| Year Ending Dec-19 | 8.58 | 8.55 | 8.54 | 8.55 | 8.09 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-18 | 8 | 3 | 10 | 4 |
| Quarter Ending Sep-18 | 3 | 8 | 3 | 11 |
| Year Ending Dec-18 | 10 | 3 | 18 | 1 |
| Year Ending Dec-19 | 8 | 7 | 11 | 8 |
| Earnings | ||||
| Quarter Ending Jun-18 | 4 | 10 | 3 | 12 |
| Quarter Ending Sep-18 | 6 | 8 | 7 | 10 |
| Year Ending Dec-18 | 9 | 3 | 14 | 2 |
| Year Ending Dec-19 | 11 | 3 | 15 | 3 |
Earnings vs. 
Estimates- Kentucky accuses J&J of contributing to opioid epidemic
- UPDATE 1-Kentucky accuses J&J of contributing to opioid epidemic
- Kentucky accuses J&J of contributing to opioid epidemic
- Exclusive: Imerys selling one billion euro tiles business, buyout funds bidding - sources
- J&J raises sales forecast but keeps profit outlook unchanged; shares drop